Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 257 entries
Sorted by: Best Match Show Resources per page
Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability.

Experimental and therapeutic medicine

Hattori H, Ishihara M.
PMID: 28450960
Exp Ther Med. 2017 Mar;13(3):1176-1180. doi: 10.3892/etm.2017.4041. Epub 2017 Jan 13.

Platelet-rich plasma (PRP) is blood plasma containing a high number of platelets that release growth factors for wound healing and tissue regeneration. In the present study, the feasibility of improving PRP therapy by using chitosan that exhibits high platelet...

Cite
Hattori H, Ishihara M. Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability. Exp Ther Med. 2017;13(3):1176-1180doi: 10.3892/etm.2017.4041.
Hattori, H., & Ishihara, M. (2017). Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability. Experimental and therapeutic medicine, 13(3), 1176-1180. https://doi.org/10.3892/etm.2017.4041
Hattori, Hidemi, and Ishihara, Masayuki. "Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability." Experimental and therapeutic medicine vol. 13,3 (2017): 1176-1180. doi: https://doi.org/10.3892/etm.2017.4041
Hattori H, Ishihara M. Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability. Exp Ther Med. 2017 Mar;13(3):1176-1180. doi: 10.3892/etm.2017.4041. Epub 2017 Jan 13. PMID: 28450960; PMCID: PMC5403699.
Copy Download .nbib Format: NLM
Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients.

Acta Cardiologica Sinica

Kuo C, Tsai CC, Chen CA, Tsai YF, Chen YH.
PMID: 28344423
Acta Cardiol Sin. 2017 Mar;33(2):188-194. doi: 10.6515/acs20160818b.

BACKGROUND: Arterial stiffness is a determinant of cardiovascular disease in end stage renal disease. Hemodialysis patients may develop anti-platelet factor 4/heparin antibody (PF4-H Ab) because of heparin treatment in dialysis. We tested whether PF4-H Ab was associated with progression...

Cite
Kuo C, Tsai CC, Chen CA, et al. Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients. Acta Cardiol Sin. 2017;33(2):188-194doi: 10.6515/acs20160818b.
Kuo, C., Tsai, C. C., Chen, C. A., Tsai, Y. F., & Chen, Y. H. (2017). Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients. Acta Cardiologica Sinica, 33(2), 188-194. https://doi.org/10.6515/acs20160818b
Kuo, Chieh, et al. "Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients." Acta Cardiologica Sinica vol. 33,2 (2017): 188-194. doi: https://doi.org/10.6515/acs20160818b
Kuo C, Tsai CC, Chen CA, Tsai YF, Chen YH. Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients. Acta Cardiol Sin. 2017 Mar;33(2):188-194. doi: 10.6515/acs20160818b. PMID: 28344423; PMCID: PMC5364161.
Copy Download .nbib Format: NLM
Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums.

World journal of critical care medicine

Gupta S, Tiruvoipati R, Green C, Botha J, Tran H.
PMID: 26261772
World J Crit Care Med. 2015 Aug 04;4(3):202-12. doi: 10.5492/wjccm.v4.i3.202. eCollection 2015 Aug 04.

Thrombocytopenia is often noted in critically ill patients. While there are many reasons for thrombocytopenia, the use of heparin and its derivatives is increasingly noted to be associated with thrombocytopenia. Heparin induced thrombocytopenia syndrome (HITS) is a distinct entity...

Cite
Gupta S, Tiruvoipati R, Green C, et al. Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums. World J Crit Care Med. 2015;4(3):202-12doi: 10.5492/wjccm.v4.i3.202.
Gupta, S., Tiruvoipati, R., Green, C., Botha, J., & Tran, H. (2015). Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums. World journal of critical care medicine, 4(3), 202-12. https://doi.org/10.5492/wjccm.v4.i3.202
Gupta, Sachin, et al. "Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums." World journal of critical care medicine vol. 4,3 (2015): 202-12. doi: https://doi.org/10.5492/wjccm.v4.i3.202
Gupta S, Tiruvoipati R, Green C, Botha J, Tran H. Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums. World J Crit Care Med. 2015 Aug 04;4(3):202-12. doi: 10.5492/wjccm.v4.i3.202. eCollection 2015 Aug 04. PMID: 26261772; PMCID: PMC4524817.
Copy Download .nbib Format: NLM
Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Demir M, Tekgündüz E, Edis M, Duran E, Kürüm T, Yiğitbaşı Ö, Yüksel M.
PMID: 27265628
Turk J Haematol. 2009 Dec 05;26(4):171-5.

OBJECTIVE: Heparin-induced thrombocytopenia (HIT) is a life threatening complication of heparin therapy, causing thrombosis. The aim of our study was to find out the frequencies of HIT antibody seroconversion and clinical HIT in Turkish medical patients on different forms...

Cite
Demir M, Tekgündüz E, Edis M, et al. Medikal hastalarda anti-heparin trombosit faktör 4 antikor ve heparine bağlı trombositopeni sıklığı. Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients. Turk J Haematol. 2009;26(4):171-5
Demir, M., Tekgündüz, E., Edis, M., Duran, E., Kürüm, T., Yiğitbaşı, �. �., & Yüksel, M. (2009). Medikal hastalarda anti-heparin trombosit faktör 4 antikor ve heparine bağlı trombositopeni sıklığı. Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients. Turkish journal of haematology : official journal of Turkish Society of Haematology, 26(4), 171-5.
Demir, Muzaffer, et al. "Medikal hastalarda anti-heparin trombosit faktör 4 antikor ve heparine bağlı trombositopeni sıklığı." Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients. Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 26,4 (2009): 171-5.
Demir M, Tekgündüz E, Edis M, Duran E, Kürüm T, Yiğitbaşı Ö, Yüksel M. Medikal hastalarda anti-heparin trombosit faktör 4 antikor ve heparine bağlı trombositopeni sıklığı. Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients. Turk J Haematol. 2009 Dec 05;26(4):171-5. PMID: 27265628.
Copy Download .nbib Format: NLM
Heparin-induced thrombocytopenia following coronary artery bypass grafting: a diagnostic dilemma.

Journal of community hospital internal medicine perspectives

Khanal R, Karmacharya P, Forman DA.
PMID: 26486110
J Community Hosp Intern Med Perspect. 2015 Oct 19;5(5):28745. doi: 10.3402/jchimp.v5.28745. eCollection 2015.

The diagnosis of heparin-induced thrombocytopenia (HIT) is a challenge in post-cardiac surgery patients because of the high incidence of non-immune thrombocytopenia and heparin-platelet factor 4 antibodies in these groups. We present a case of HIT in a post coronary...

Cite
Khanal R, Karmacharya P, Forman DA. Heparin-induced thrombocytopenia following coronary artery bypass grafting: a diagnostic dilemma. J Community Hosp Intern Med Perspect. 2015;5(5):28745doi: 10.3402/jchimp.v5.28745.
Khanal, R., Karmacharya, P., & Forman, D. A. (2015). Heparin-induced thrombocytopenia following coronary artery bypass grafting: a diagnostic dilemma. Journal of community hospital internal medicine perspectives, 5(5), 28745. https://doi.org/10.3402/jchimp.v5.28745
Khanal, Raju, et al. "Heparin-induced thrombocytopenia following coronary artery bypass grafting: a diagnostic dilemma." Journal of community hospital internal medicine perspectives vol. 5,5 (2015): 28745. doi: https://doi.org/10.3402/jchimp.v5.28745
Khanal R, Karmacharya P, Forman DA. Heparin-induced thrombocytopenia following coronary artery bypass grafting: a diagnostic dilemma. J Community Hosp Intern Med Perspect. 2015 Oct 19;5(5):28745. doi: 10.3402/jchimp.v5.28745. eCollection 2015. PMID: 26486110; PMCID: PMC4612479.
Copy Download .nbib Format: NLM
Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4).

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Bertling A, Brodde MF, Visser M, Treffon J, Fennen M, Fender AC, Kelsch R, Kehrel BE.
PMID: 29070980
Transfus Med Hemother. 2017 Sep;44(5):351-357. doi: 10.1159/000472157. Epub 2017 Aug 11.

BACKGROUND: Hemarthrosis, or bleeding into the joints, is a hallmark of hemophilia. Heme triggers oxidative stress, inflammation, and destruction of cartilage and bone. The haptoglobin-CD163-heme oxygenase-1 (HO-1) pathway circumvents heme toxicity through enzymatic degradation of heme and transcription of...

Cite
Bertling A, Brodde MF, Visser M, et al. Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4). Transfus Med Hemother. 2017;44(5):351-357doi: 10.1159/000472157.
Bertling, A., Brodde, M. F., Visser, M., Treffon, J., Fennen, M., Fender, A. C., Kelsch, R., & Kehrel, B. E. (2017). Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4). Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 44(5), 351-357. https://doi.org/10.1159/000472157
Bertling, Anne, et al. "Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4)." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 44,5 (2017): 351-357. doi: https://doi.org/10.1159/000472157
Bertling A, Brodde MF, Visser M, Treffon J, Fennen M, Fender AC, Kelsch R, Kehrel BE. Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4). Transfus Med Hemother. 2017 Sep;44(5):351-357. doi: 10.1159/000472157. Epub 2017 Aug 11. PMID: 29070980; PMCID: PMC5649264.
Copy Download .nbib Format: NLM
Hemostasis and Thrombosis: Clinical Usefulness of Combined use of Platelet Aggregation Test and Anti PF4-H. Antibodies Elisa test for the Diagnosis of Heparin Induced Thrombocytopenia.

Hematology (Amsterdam, Netherlands)

Rugeri L, Bauters A, Trillot N, Susen S, Decoen C, Watel A, Jude B.
PMID: 11399578
Hematology. 1999;4(4):367-372. doi: 10.1080/10245332.1999.11746461.

Background. Heparin is the most commonly used drug in patients requiring therapeutic anticoagulation. But the use of heparin has serious side effects such as heparin-induced thrombocytopenia (HIT). The diagnosis of HIT is often difficult. This study was designed to...

Cite
Rugeri L, Bauters A, Trillot N, et al. Hemostasis and Thrombosis: Clinical Usefulness of Combined use of Platelet Aggregation Test and Anti PF4-H. Antibodies Elisa test for the Diagnosis of Heparin Induced Thrombocytopenia. Hematology. 1999;4(4):367-372doi: 10.1080/10245332.1999.11746461.
Rugeri, L., Bauters, A., Trillot, N., Susen, S., Decoen, C., Watel, A., & Jude, B. (1999). Hemostasis and Thrombosis: Clinical Usefulness of Combined use of Platelet Aggregation Test and Anti PF4-H. Antibodies Elisa test for the Diagnosis of Heparin Induced Thrombocytopenia. Hematology (Amsterdam, Netherlands), 4(4), 367-372. https://doi.org/10.1080/10245332.1999.11746461
Rugeri, L., et al. "Hemostasis and Thrombosis: Clinical Usefulness of Combined use of Platelet Aggregation Test and Anti PF4-H. Antibodies Elisa test for the Diagnosis of Heparin Induced Thrombocytopenia." Hematology (Amsterdam, Netherlands) vol. 4,4 (1999): 367-372. doi: https://doi.org/10.1080/10245332.1999.11746461
Rugeri L, Bauters A, Trillot N, Susen S, Decoen C, Watel A, Jude B. Hemostasis and Thrombosis: Clinical Usefulness of Combined use of Platelet Aggregation Test and Anti PF4-H. Antibodies Elisa test for the Diagnosis of Heparin Induced Thrombocytopenia. Hematology. 1999;4(4):367-372. doi: 10.1080/10245332.1999.11746461. PMID: 11399578.
Copy Download .nbib Format: NLM
Commentary: Everett BM, et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007;83:592-597.

Perspectives in vascular surgery and endovascular therapy

Jackson MR.
PMID: 18403474
Perspect Vasc Surg Endovasc Ther. 2008 Mar;20(1):102-3. doi: 10.1177/1531003507310836.

No abstract available.

Cite
Jackson MR. Commentary: Everett BM, et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007;83:592-597. Perspect Vasc Surg Endovasc Ther. 2008;20(1):102-3doi: 10.1177/1531003507310836.
Jackson, M. R. (2008). Commentary: Everett BM, et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007;83:592-597. Perspectives in vascular surgery and endovascular therapy, 20(1), 102-3. https://doi.org/10.1177/1531003507310836
Jackson, Mark R. "Commentary: Everett BM, et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007;83:592-597." Perspectives in vascular surgery and endovascular therapy vol. 20,1 (2008): 102-3. doi: https://doi.org/10.1177/1531003507310836
Jackson MR. Commentary: Everett BM, et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007;83:592-597. Perspect Vasc Surg Endovasc Ther. 2008 Mar;20(1):102-3. doi: 10.1177/1531003507310836. PMID: 18403474.
Copy Download .nbib Format: NLM
[Two cases of heparin-induced thrombocytopenia diagnosed by particle gel immunoassay.].

The Korean journal of laboratory medicine

Song KS, Chang SH, Suh JS.
PMID: 18156747
Korean J Lab Med. 2006 Oct;26(5):334-7. doi: 10.3343/kjlm.2006.26.5.334.

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy. It represents initially as thrombocytopenia and is associated with venous or arterial thrombosis. It has been reported that platelet factor 4/heparin complex antibody plays an important role in the...

Cite
Song KS, Chang SH, Suh JS. [Two cases of heparin-induced thrombocytopenia diagnosed by particle gel immunoassay.]. Korean J Lab Med. 2006;26(5):334-7doi: 10.3343/kjlm.2006.26.5.334.
Song, K. S., Chang, S. H., & Suh, J. S. (2006). [Two cases of heparin-induced thrombocytopenia diagnosed by particle gel immunoassay.]. The Korean journal of laboratory medicine, 26(5), 334-7. https://doi.org/10.3343/kjlm.2006.26.5.334
Song, Kyu Sub, et al. "[Two cases of heparin-induced thrombocytopenia diagnosed by particle gel immunoassay.]." The Korean journal of laboratory medicine vol. 26,5 (2006): 334-7. doi: https://doi.org/10.3343/kjlm.2006.26.5.334
Song KS, Chang SH, Suh JS. [Two cases of heparin-induced thrombocytopenia diagnosed by particle gel immunoassay.]. Korean J Lab Med. 2006 Oct;26(5):334-7. doi: 10.3343/kjlm.2006.26.5.334. Korean. PMID: 18156747.
Copy Download .nbib Format: NLM
Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.

Expert review of pharmacoeconomics & outcomes research

Wade WE, Spruill WJ.
PMID: 20528310
Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):227-37. doi: 10.1586/14737167.7.3.227.

Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby...

Cite
Wade WE, Spruill WJ. Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. Expert Rev Pharmacoecon Outcomes Res. 2007;7(3):227-37doi: 10.1586/14737167.7.3.227.
Wade, W. E., & Spruill, W. J. (2007). Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. Expert review of pharmacoeconomics & outcomes research, 7(3), 227-37. https://doi.org/10.1586/14737167.7.3.227
Wade, William E, and Spruill, William J. "Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism." Expert review of pharmacoeconomics & outcomes research vol. 7,3 (2007): 227-37. doi: https://doi.org/10.1586/14737167.7.3.227
Wade WE, Spruill WJ. Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):227-37. doi: 10.1586/14737167.7.3.227. PMID: 20528310.
Copy Download .nbib Format: NLM
Molecular biology studies with primary megakaryocytes.

Methods in molecular medicine

Shou Y, Poncz M.
PMID: 21341010
Methods Mol Med. 1999;31:347-54. doi: 10.1385/1-59259-248-1:347.

Megakaryocytes are rare hematopoietic cells comprising only about 0.02-0.05% of the bone marrow nucleated cell population. Because of the relative infrequency of megakaryocytes in the bone marrow and their fragility in vitro, studies to characterize expression of platelet-specific genes...

Cite
Shou Y, Poncz M. Molecular biology studies with primary megakaryocytes. Methods Mol Med. 1999;31:347-54doi: 10.1385/1-59259-248-1:347.
Shou, Y., & Poncz, M. (1999). Molecular biology studies with primary megakaryocytes. Methods in molecular medicine, 31347-54. https://doi.org/10.1385/1-59259-248-1:347
Shou, Y, and Poncz, M. "Molecular biology studies with primary megakaryocytes." Methods in molecular medicine vol. 31 (1999): 347-54. doi: https://doi.org/10.1385/1-59259-248-1:347
Shou Y, Poncz M. Molecular biology studies with primary megakaryocytes. Methods Mol Med. 1999;31:347-54. doi: 10.1385/1-59259-248-1:347. PMID: 21341010.
Copy Download .nbib Format: NLM
Pulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH.

The American journal of case reports

Kumar M, Abrina VM, Chittimireddy S.
PMID: 23569505
Am J Case Rep. 2012;13:118-21. doi: 10.12659/AJCR.883107. Epub 2012 Jun 20.

BACKGROUND: Heparin induced thrombocytopenia (HIT) is a serious complication associated with heparin use. HIT usually develops between 5-14 days after starting heparin. Delayed-onset HIT can still occur 9-45 days after heparin had been discontinued. In patients with delayed HIT,...

Cite
Kumar M, Abrina VM, Chittimireddy S. Pulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH. Am J Case Rep. 2012;13:118-21doi: 10.12659/AJCR.883107.
Kumar, M., Abrina, V. M., & Chittimireddy, S. (2012). Pulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH. The American journal of case reports, 13118-21. https://doi.org/10.12659/AJCR.883107
Kumar, Mehandar, et al. "Pulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH." The American journal of case reports vol. 13 (2012): 118-21. doi: https://doi.org/10.12659/AJCR.883107
Kumar M, Abrina VM, Chittimireddy S. Pulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH. Am J Case Rep. 2012;13:118-21. doi: 10.12659/AJCR.883107. Epub 2012 Jun 20. PMID: 23569505; PMCID: PMC3616178.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 257 entries